復星醫藥(600196.SH)子公司擬對復星凱特等比例增資1000萬美元
格隆匯7月6日丨復星醫藥(600196.SH)公佈,2020年7月6日,控股子公司復星醫藥產業與Kite Pharma簽訂《中外合作經營合同之修正案(四)》,復星醫藥產業與Kite Pharma擬根據各自所持復星凱特股權比例對復星凱特進行增資,其中:復星醫藥產業擬以等值於1000萬美元的人民幣(匯率按實際出資日中國人民銀行公佈的美元和人民幣之間的中間價折算)現金認繳復星凱特新增註冊資本1000萬美元(以下簡稱“本次投資”或“本次關聯交易”)、Kite Pharma擬以1000萬美元現金認繳復星凱特新增註冊資本1000萬美元。
本次增資完成後,復星凱特的註冊資本將由6600萬美元增至8600萬美元,其中:復星醫藥產業仍將持有復星凱特50%的股權;復星凱特仍為公司合營企業。
復星凱特系集團投資的合營企業,其在研產品阿基侖賽注射液(FKC876)已完成用於治療成人復發難治性大B細胞淋巴瘤的中國境內橋接臨牀試驗,該產品的上市註冊申請已獲國家藥品監督管理局審評受理並已納入藥品上市註冊優先審評程序。本次復星凱特各方股東根據各自所持其股權比例對復星凱特進行增資主要係為復星凱特後續研發和生產提供資金支持,以供進一步推進相關產品的研發和產業化進程。復星醫藥產業將以自籌資金支付本次投資的對價。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.